Helen Collins, Chief Medical Officer of Enliven Therapeutics, sold 5,000 shares for $198,971 on May 18, 2026. Prices ranged from $38.855 to $41.605 per share.
Collins also exercised options for 5,000 shares at $2.48 each. She now directly holds 25,000 shares.
Updated data on ELVN-001 for chronic myeloid leukemia will be presented at EHA. 38% of patients achieved major molecular response by 24 weeks.
Price targets: Guggenheim $80, H.C. Wainwright $56, Clear Street $36.
